Patents by Inventor Olivier Freytag

Olivier Freytag has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES FOR CHELATED RADIONUCLIDES AND CLEARING AGENTS
    Publication number: 20220031871
    Abstract: The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies, It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. It additionally relates to clearing agents and useful in such methods.
    Type: Application
    Filed: April 16, 2019
    Publication date: February 3, 2022
    Applicants: Hoffmann-La Roche Inc., Orano Med SAS
    Inventors: Julien TORGUE, Paul JUREK, Federico ROJAS-QUIJANO, Garry E. KIEFER, Olivier FREYTAG, Christian GERDES, Christian KLEIN, Pablo UMANA, Alexander HAAS, Sofia FROST, Amal SAIDI, Tapan NAYAK
  • COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20200095313
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: December 11, 2019
    Publication date: March 26, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Emily Rana CORSE, Olivier FREYTAG, Christian GERDES, Marine LE CLECH, Hyam LEVITSKY, Marion OTT, Martin STERN, Wei XU
  • COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20180051077
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: October 2, 2017
    Publication date: February 22, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Emily Rana Corse, Olivier Freytag, Christian Gerdes, Marine Le Clech, Hyam Levitsky, Marion OTT, Martin Stern, Wei Xu
  • Anti-MCSP antibodies
    Patent number: 9309306
    Abstract: The invention provides anti-MCSP antibodies and methods of using the same.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: April 12, 2016
    Assignee: Roche Glycart AG
    Inventors: Olivier Freytag, Guy Georges, Ekkehard Moessner, Olaf Mundigl, Gérald Tuffin, Pablo Umana
  • COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20160045597
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: August 14, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Emily Rana CORSE, Olivier FREYTAG, Christian GERDES, Marine LE CLECH, Hyam LEVITSKY, Marion OTT, Martin STERN, Wei XU
  • ANTI-MCSP ANTIBODIES
    Publication number: 20130078251
    Abstract: The invention provides anti-MCSP antibodies and methods of using the same.
    Type: Application
    Filed: August 21, 2012
    Publication date: March 28, 2013
    Inventors: Olivier Freytag, Guy Georges, Ekkehard Moessner, Olaf Mundigl, Gérald Tuffin, Pablo Umana